Scrip Awards 2019
The 15th Annual Scrip Awards
4 December 2019
We are delighted to announce the shortlist for the 15th Annual Scrip Awards. Click here to see the full list.
Since they began, the Scrip Awards has sought to applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare. Its trophies span the entire range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and fundraising.
This year, we have introduced a new category – MSD’s Innovation Award – to acknowledge and celebrate the outstanding scientific or technological breakthroughs that have the potential to be transformative in the discovery or development of new medicines.
Over the past 15 years, the Scrip Awards has carved out a unique place in the industry calendar, with around 500 attendees coming from around the world to the prestigious ceremony, which this year will take place in the London Hilton on Park Lane in Mayfair on 4 December. Don't forget to book your table to be in the room when the winners are announced.
IQVIA™ is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward.
IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of Human Data Science a reality. IQVIA’s approach to Human Data Science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, advanced technology and analytics with extensive industry knowledge. To learn more, visit www.iqvia.com.
CMIC stands for Current Medical Information Center. In 1992, Dr. Kazuo Nakamura founded CMIC as the first Contract Research Organization (CRO) in Japan. CMIC Group is currently the largest clinical CRO in Japan, providing comprehensive services in drug development, clinical trial and clinical site management, clinical to commercial GMP manufacturing, regulatory consulting and contract sales & marketing solutions. We can help pharmaceutical, biotech and medical device companies to enter Japan market, to conduct clinical trials in Asia, or to bridge your drug development and manufacturing needs between the US and Japan. CMIC Group has over 7,000 employees and 25 sites globally.
Masters Speciality Pharma is a global pharmaceutical company with a vision to provide access to excellence in medicines for all, with a priority in the Emerging Markets. Headquartered in the UK with subsidiaries in USA, Brazil, El-Salvador and Uruguay, Masters operates as two divisions; Masters Speciality Access (MSA), an end to end supply of unlicensed medicines for unmet and life threatening medical needs. Masters Speciality Medicines (MSM) provides healthcare professionals, clinics and hospitals with a reliable and affordable source of high quality medicines, which are locally registered under Masters’ name. All delivered with comprehensive regulatory compliance and global pharmacovigilance.
Medidata is leading the digital transformation of life sciences, with the world's most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by the #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users every day to create hope for millions of patients. Discover the future of life sciences: www.mdsol.com
MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our European Innovation Hub (located in London) is embedded in one of Europe’s key scientific communities to drive engagement with local academia, biotech, peer pharma and venture capitalists. The Hub includes a Business Development & Licensing team, Clinical teams and our UK Discovery Research Centre. The Centre, established in 2018, will drive scientific and medical advances against some of the most challenging diseases facing ageing populations. It will initially focus on the study of changes in the fundamental mechanisms of cell homeostasis and resilience in the context of ageing that lead to disease.
Globally, with more than 100 significant business development transactions since 2017, our team has experience working on collaborations from discovery through clinical-stage programs. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life. Learn more at msd.com/licensing.
Skipta is the leading social network of specialized online medical communities for verified healthcare professionals (HCPs). Skipta’s growing network of more than 30 specialty communities allow verified HCPs to communicate and collaborate with peers in a focused, secure environment. The company enables pharmaceutical and biotech brands to drive awareness and behaviour change by bringing to them multi-channel access to verified HCPs through integrated engagement programs.
Syneos Health is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry-leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, immune-mediated inflammatory disorders (IMID), oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. http://www.worldwide.com.
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,600 collaborators from over 30 countries to improve the health of those in need – and to fulfill our dream that "every drug can be made and every disease can be treated."